InspireMD Inc (NYSEAMERICAN:NSPR) shares were down 6.7% during trading on Tuesday . The company traded as low as $0.13 and last traded at $0.14. Approximately 3,291,348 shares traded hands during mid-day trading, an increase of 163% from the average daily volume of 1,251,330 shares. The stock had previously closed at $0.15.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of InspireMD in a research note on Wednesday, March 13th.

Shares of InspireMD are scheduled to reverse split on the morning of Monday, April 1st. The 1-50 reverse split was announced on Tuesday, March 26th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, March 29th.

InspireMD (NYSEAMERICAN:NSPR) last issued its earnings results on Tuesday, February 19th. The medical equipment provider reported ($0.05) EPS for the quarter. The business had revenue of $0.82 million during the quarter.

An institutional investor recently bought a new position in InspireMD stock. Barclays PLC bought a new position in shares of InspireMD Inc (NYSEAMERICAN:NSPR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 162,797 shares of the medical equipment provider’s stock, valued at approximately $26,000. Barclays PLC owned approximately 0.39% of InspireMD at the end of the most recent quarter.

WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at

InspireMD Company Profile (NYSEAMERICAN:NSPR)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

See Also: What are no-load funds?

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.